Henogen invests 5 million Euros in its newly acquriered mammalian cell production site

10-Dec-2003
Brussels - Henogen, an integrated bioengineering and pharmaceutical company located at Charleroi in Belgium, announced a 5 Million Euros investment to upgrade its newly acquired mammalian products R&D facility ( formerly known as 4C Biotech, Belgium) to the cGMP standards required for the production of biopharmaceuticals e.g. monoclonal antibodies. "This investment will enable Henogen to implement new GMP suites featuring a 300L bioreactor train on top of its existing park of 15 & 60L bioreactors used for process development purposes," said Dr Alex Bollen, CEO. "This new cGMP pilot plant, operated in both fed-batch and perfusion modes, will be available in the late 2004 to deliver clinical-grade biotherapeutics at a scale appropriate to the phase I and II clinical trials," he added. This investment extends the existing know-how of Henogen - from gene to clinical product - to the large scale production of clinical grade monoclonal antibodies and recombinant proteins.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures
View topic world
Topic world biopharmaceutical manufacturing

Topic world biopharmaceutical manufacturing

Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.

20+ products
15+ brochures